Cargando…

Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence

Autoimmune hepatitis (AIH) was defined as a progressive, chronic inflammatory autoimmune liver disease (ALD). The diagnosis of AIH requires the presence of characteristic clinical and laboratory features, and the exclusion of other clinical conditions that cause chronic hepatitis and cirrhosis. AIH...

Descripción completa

Detalles Bibliográficos
Autores principales: Assandri, Roberto, Montanelli, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035537/
https://www.ncbi.nlm.nih.gov/pubmed/33868616
_version_ 1783676719660531712
author Assandri, Roberto
Montanelli, Alessandro
author_facet Assandri, Roberto
Montanelli, Alessandro
author_sort Assandri, Roberto
collection PubMed
description Autoimmune hepatitis (AIH) was defined as a progressive, chronic inflammatory autoimmune liver disease (ALD). The diagnosis of AIH requires the presence of characteristic clinical and laboratory features, and the exclusion of other clinical conditions that cause chronic hepatitis and cirrhosis. AIH can have an acute onset that mimics an acute viral or toxic hepatitis or an acute severe (fulminant, ASF) presentation that satisfies criteria for acute liver. Guidelines from the European Association for the Study of Liver Diseases define ALF with absence of pre-existing liver disease, acute onset of ≤ 26 weeks, coagulopathy (international normalised ratio (INR) ≥ 1.5), and presence of hepatic encephalopathy (HE). In recent years, autoantibodies (Aab) targeting subcellular structures described as the rods and rings (R&R) pattern in HEp-2 ANA have been presented as a unique and particular case of Aab generation. These R&R structures are composed of inosine monophosphate dehydrogenase type 2 (IMPDH2), and their formation can be induced in vitro by several small-molecule inhibitors. Aab targeting these relatively unknown structures has been observed in Hepatitis C virus (HCV) patients who have undergone treatment with pegylated interferona/ ribavirin (IFN/RBV) therapy. We presented and characterized a case patient with R&R and SMA Aab in AIH (ASF, fatal, without liver transplantation). To the best of our knowledge, this is the first evidence described in the Literature. Our early experience showed the R&R circulating Aab in one patient with Primary Biliary Cholangitis. This work now demonstrates that R&R Aab can also be present in AIH case.
format Online
Article
Text
id pubmed-8035537
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-80355372021-04-16 Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence Assandri, Roberto Montanelli, Alessandro Gastroenterol Hepatol Bed Bench Case Report Autoimmune hepatitis (AIH) was defined as a progressive, chronic inflammatory autoimmune liver disease (ALD). The diagnosis of AIH requires the presence of characteristic clinical and laboratory features, and the exclusion of other clinical conditions that cause chronic hepatitis and cirrhosis. AIH can have an acute onset that mimics an acute viral or toxic hepatitis or an acute severe (fulminant, ASF) presentation that satisfies criteria for acute liver. Guidelines from the European Association for the Study of Liver Diseases define ALF with absence of pre-existing liver disease, acute onset of ≤ 26 weeks, coagulopathy (international normalised ratio (INR) ≥ 1.5), and presence of hepatic encephalopathy (HE). In recent years, autoantibodies (Aab) targeting subcellular structures described as the rods and rings (R&R) pattern in HEp-2 ANA have been presented as a unique and particular case of Aab generation. These R&R structures are composed of inosine monophosphate dehydrogenase type 2 (IMPDH2), and their formation can be induced in vitro by several small-molecule inhibitors. Aab targeting these relatively unknown structures has been observed in Hepatitis C virus (HCV) patients who have undergone treatment with pegylated interferona/ ribavirin (IFN/RBV) therapy. We presented and characterized a case patient with R&R and SMA Aab in AIH (ASF, fatal, without liver transplantation). To the best of our knowledge, this is the first evidence described in the Literature. Our early experience showed the R&R circulating Aab in one patient with Primary Biliary Cholangitis. This work now demonstrates that R&R Aab can also be present in AIH case. Shaheed Beheshti University of Medical Sciences 2021 /pmc/articles/PMC8035537/ /pubmed/33868616 Text en ©2021 RIGLD, Research Institute for Gastroenterology and Liver Diseases https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Assandri, Roberto
Montanelli, Alessandro
Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title_full Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title_fullStr Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title_full_unstemmed Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title_short Acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
title_sort acute severe autoimmune hepatitis with anti-rods and rings autoantibodies; literature first evidence
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035537/
https://www.ncbi.nlm.nih.gov/pubmed/33868616
work_keys_str_mv AT assandriroberto acutesevereautoimmunehepatitiswithantirodsandringsautoantibodiesliteraturefirstevidence
AT montanellialessandro acutesevereautoimmunehepatitiswithantirodsandringsautoantibodiesliteraturefirstevidence